Home / Compounds / HGH 191aa
Tier S Growth Hormone Available to enquire

HGH 191aa

Recombinant Human Growth Hormone (Somatropin) — 191 Amino Acid Sequence

The gold standard — recombinant somatropin, identical to endogenous HGH. S-tier by FDA approval and decades of clinical data.

Tier S — FDA-Approved: Overwhelming human data — approved and prescribed. How our tiers work →
Enquire on WhatsApp →

Research facts

Half-life~3.4h SubQ / ~20 min IV
RouteSubQ / IM
Typical dose1–4 IU/day
FrequencyOnce daily (bedtime or AM fasted)
SolventBacteriostatic water
pH6.0–8.0
Stability30 days at +4°C

Mechanism of action

HGH 191aa is recombinant human Growth Hormone (rHGH/Somatropin) — the identical 191 amino acid, 22 kDa polypeptide sequence to endogenous pituitary GH. Biosynthetically produced via E. coli or mammalian cell expression, it is the most pharmacologically characterised peptide in this library.

It binds to GH receptors (GHR) on hepatocytes and peripheral tissues, triggering JAK2/STAT5 signalling for IGF-1 synthesis and direct tissue effects. Metabolic actions include lipolysis via hormone-sensitive lipase activation, anti-insulin effects (glucose-sparing), lean mass preservation, and nitrogen retention. It promotes longitudinal bone growth via GH receptor activation in growth plates.

Multiple FDA approvals (Genotropin, Norditropin, Humatrope) for GH deficiency, Turner syndrome, Prader-Willi, HIV wasting, SGA, and adult GH deficiency. The S-tier designation reflects this extraordinary clinical evidence base. Off-label use in anti-ageing and body composition represents a separate, less regulated space.

Documented effects (research-model)

  • Proven lean mass preservation and fat reduction (multiple Phase III RCTs)
  • Bone density improvement (FDA-approved indication)
  • IGF-1 elevation for tissue anabolism and anti-ageing
  • Metabolic rate increase via increased lean mass
  • Sleep quality and slow-wave sleep enhancement
  • Wound healing acceleration in clinical trials

Research protocols

ProtocolDoseFrequencyCycleVial
Standard 1–2 IU/day Once daily SubQ (bedtime) 3–6 months 10 IU / BAC water per vial
Advanced 2–4 IU/day Once daily or split AM + PM 6 months cycles 10–36 IU per kit

Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.

Synergies

  • Tesamorelin LOW
    Redundant if using both HGH and GHRH analogues — both elevate GH/IGF-1 via different mechanisms. Choose one approach.
  • Ipamorelin LOW
    Typically not combined with exogenous HGH — GHRP becomes redundant when pituitary is bypassed.

Myths & misconceptions

Myth More IU = faster results.
Reality Research and clinical practice show a dose-response curve with significant diminishing returns above 2–3 IU in adult GH-replete individuals. Higher doses proportionally increase side effects (fluid retention, carpal tunnel, acromegaly risk) without proportional benefit.
Myth HGH is only for elite athletes and cheaters.
Reality HGH has 7+ FDA-approved indications for legitimate medical conditions. Anti-ageing use is off-label in adults without GH deficiency. The evidence for benefits in GH-sufficient adults is far weaker than for deficient populations.

Evidence gaps

  • Long-term safety of anti-ageing doses in GH-sufficient adults is understudied.
  • Whether exogenous HGH accelerates latent tumour growth in healthy adults is a genuine unresolved concern.
  • Optimal anti-ageing dose vs. therapeutic dose distinction is not established in prospective trials.

Safety notes

Contraindicated in active malignancy, acute illness. Monitor glucose, IGF-1, thyroid function. Fluid retention, carpal tunnel, acromegaly at high doses. Prescription-only in UK/US/EU. Research use only in this context.

Biomarkers to monitor

IGF-1Fasting GlucoseHbA1cInsulinTSHT3/T4

Primary-source citations

  • PMID 12375184 — Growth hormone therapy in adults: a systematic review (Endocr Rev. 2002)

Frequently asked

What is HGH 191aa?

HGH 191aa (Recombinant Human Growth Hormone (Somatropin) — 191 Amino Acid Sequence) is a research compound classified in our library as Tier S — Overwhelming human data — approved and prescribed.. The gold standard — recombinant somatropin, identical to endogenous HGH. S-tier by FDA approval and decades of clinical data.

What is the evidence tier for HGH 191aa?

We classify HGH 191aa as Tier S: Overwhelming human data — approved and prescribed. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.

What is the research dose of HGH 191aa?

For HGH 191aa, typical research dose is 1–4 IU/day, route is SubQ / IM, half-life is ~3.4h SubQ / ~20 min IV. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.

Is HGH 191aa safe?

Contraindicated in active malignancy, acute illness. Monitor glucose, IGF-1, thyroid function. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.

Free 60-compound reference

Get the Master Research Protocol Reference

Every compound in our library — mechanism, dosing, protocols, biomarkers, primary-source citations. One PDF, delivered to your inbox. No spam, one email, unsubscribe anytime.

Research-use only. Not medical advice. Read our privacy policy.

Open HGH 191aa in the peptide library → Enquire about HGH 191aa on WhatsApp →